{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:50:05Z","timestamp":1762869005279,"version":"3.41.2"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>With the introduction of biological disease-modifying antirheumatic drugs (bDMARDs), the treatment of pediatric patients with autoimmune\/inflammatory rheumatic diseases (pedAIIRD) has advanced from the \u201cStone Age\u201d to modern times, resulting in much better clinical outcomes. However, everything comes with a price, and use of new bDMARDs has resulted in an increased risk of infections. Therefore, preventing infections in pedAIIRD patients is one of the top priorities. The most effective preventive measure against infection is vaccination. The first study on humoral immunity after vaccination in pediatric rheumatology was published in 1974 and on safety in 1993. For many years, data about safety and immunogenicity in pedAIIRD patients were available only for non-live vaccines and the first studies on live-attenuated vaccines in pedAIIRD patients treated with immunosuppressive therapy were available only after 2007. Even today the data are limited, especially for children treated with bDMARDs. Vaccinations with non-live vaccines are nowadays recommended, although their long-term immunogenicity and efficacy in pedAIIRD patients are still under investigation. Vaccinations with live-attenuated vaccines are not universally recommended in immunosuppressed patients. However, measles-mumps-rubella booster and varicella zoster virus vaccination can be considered under specific conditions. Additional research is needed to provide more evidence on safety and immunogenicity, especially regarding live-attenuated vaccines in immunosuppressed patients with pedAIIRD. Due to the limited number of these patients, well-designed, prospective, international studies are needed. Further challenges were presented by the COVID-19 pandemic. This mini review article reviews past and present data and discusses the future of vaccinology in pediatric rheumatology.<\/jats:p>","DOI":"10.3389\/fped.2022.1098332","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T21:40:05Z","timestamp":1673386805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Vaccinology in pediatric rheumatology: Past, present and future"],"prefix":"10.3389","volume":"10","author":[{"given":"Masa","family":"Bizjak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merav","family":"Heshin-Bekenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H. A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskya","family":"Angevare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosef","family":"Uziel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaas M.","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasa","family":"Toplak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the PReS Vaccination Working Party","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11926-013-0322-6","article-title":"Diagnosis and management of infectious complications of childhood rheumatic diseases","volume":"15","author":"Castillo","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11926-013-0327-1","article-title":"Infectious complications in juvenile idiopathic arthritis","volume":"15","author":"Hurd","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s10067-018-4367-9","article-title":"The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study","volume":"38","author":"Aygun","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","article-title":"Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from pharmachild and national registries","volume":"20","author":"Swart","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/ard.33.3.248","article-title":"Humoral immunity in juvenile rheumatoid arthritis","volume":"33","author":"Hoyeraal","year":"1974","journal-title":"Ann Rheum Dis"},{"key":"B7","first-page":"1769","article-title":"Influenza immunization in children with chronic arthritis: a prospective study","volume":"20","author":"Malleson","year":"1993","journal-title":"J Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1136\/ard.2006.063586","article-title":"Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis","volume":"66","author":"Heijstek","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222574","article-title":"EULAR\/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021","author":"Jansen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B10","first-page":"164","article-title":"Vaccination coverage in children with rheumatic diseases","volume":"38","author":"Bizjak","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00393-007-0150-z","article-title":"Immunization in children and adolescents with rheumatic diseases","volume":"66","author":"Minden","year":"2007","journal-title":"Z Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1093\/rheumatology\/kes175","article-title":"Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre","volume":"51","author":"Morin","year":"2012","journal-title":"Rheumatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/ard.2011.150193","article-title":"EULAR recommendations for vaccination in paediatric patients with rheumatic diseases","volume":"70","author":"Heijstek","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"910026","DOI":"10.3389\/fped.2022.910026","article-title":"Efficacy, immunogenicity and safety of vaccination in pediatric patients with autoimmune inflammatory rheumatic diseases (pedAIIRD): a systematic literature review for the 2021 update of the EULAR\/PRES recommendations","volume":"10","author":"Jansen","year":"2022","journal-title":"Front Pediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11926-020-00905-8","article-title":"Vaccination for children on biologics","volume":"22","author":"Toplak","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-018-0265-6","article-title":"Paediatric rheumatology European society: PReS vaccination working group. Challenges in achieving consensus for vaccination with live attenuated vaccines in children with rheumatological disease\u2014the variability of vaccination practices across the globe. Proceedings of the 25th European paediatric rheumatology congress (PReS 2018): Lisbon, Portugal","volume":"16","author":"Toplak","year":"2018","journal-title":"Pediatr Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1016\/j.vaccine.2021.04.065","article-title":"Charting mandatory childhood vaccination policies worldwide","volume":"39","author":"Vanderslott","year":"2021","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-019-02193-4","article-title":"Vaccination rates rise in Italy and France after law change","author":"Warren","year":"2019","journal-title":"Nature"},{"year":"","key":"B19"},{"year":"","key":"B20"},{"year":"","key":"B21"},{"year":"","key":"B22"},{"year":"","key":"B23"},{"year":"","key":"B24"},{"year":"","key":"B25"},{"year":"","key":"B26"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.3390\/ijerph19074140","article-title":"Measles vaccination and outbreaks in Croatia from 2001 to 2019; A comparative study to other European countries","volume":"19","author":"Drenjan\u010devi\u0107","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1186\/s12879-021-06927-6","article-title":"Number of doses of measles-mumps-Rubella vaccine applied in Brazil before and during the COVID-19 pandemic","volume":"21","author":"da Silva","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijerph18030988","article-title":"The impact of the COVID-19 pandemic on immunization campaigns and programs: a systematic review","volume":"18","author":"Lassi","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"666848","DOI":"10.3389\/fped.2021.666848","article-title":"Mandatory infant vaccinations in France during the COVID-19 pandemic in 2020","volume":"9","author":"Taine","year":"2021","journal-title":"Front Pediatr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/acr.21948","article-title":"High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus","volume":"65","author":"Campos","year":"2013","journal-title":"Arthritis Care Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"822885","DOI":"10.3389\/fimmu.2022.822885","article-title":"B cell characteristics at baseline predict vaccination response in RTX treated patients","volume":"13","author":"Stefanski","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/annrheumdis-2012-202561","article-title":"Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis","volume":"73","author":"Stoof","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.vaccine.2011.11.08","article-title":"Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis","volume":"30","author":"Dell\u2019Era","year":"2012","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1546-0096-11-10","article-title":"Prospective surveillance study of acute respiratory infections, influenza-like illness and seasonal influenza vaccine in a cohort of juvenile idiopathic arthritis patients","volume":"11","author":"Carvalho","year":"2013","journal-title":"Pediatr Rheumatol Online J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3109\/14397595.2015.1085608","article-title":"The safety and effectiveness of HBV vaccination in patients with juvenile idiopathic arthritis controlled by treatment","volume":"26","author":"Nerome","year":"2016","journal-title":"Mod Rheumatol"},{"key":"B37","first-page":"882","article-title":"Paediatric rheumatology hepatitis B vaccination in juvenile systemic lupus erythematosus","volume":"29","author":"Aytac","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/03009742.2012.709272","article-title":"Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis","volume":"42","author":"Aikawa","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12969-017-0190-0","article-title":"Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay","volume":"15","author":"Camacho-Lovillo","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10165-012-0595-z","article-title":"Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab","volume":"22","author":"Shinoki","year":"2012","journal-title":"Mod Rheumatol"},{"key":"B41","first-page":"436","article-title":"Paediatric rheumatology safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis","volume":"30","author":"Toplak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/ped.14533","article-title":"Efficacy of hepatitis B vaccination in children with rheumatic diseases","volume":"63","author":"Kohagura","year":"2021","journal-title":"Pediatr Int"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1177\/0961203318808589","article-title":"Immunogenicity of sequential 13-valent conjugated and 23-valent unconjugated pneumococcal vaccines in a population of children with lupus","volume":"27","author":"Gorelik","year":"2018","journal-title":"Lupus"},{"key":"B44","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.vaccine.2014.12.030","article-title":"Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy","volume":"33","author":"Aikawa","year":"2015","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/art.39482","article-title":"Brief report: severe inflammation following vaccination against Streptococcus pneumoniae in patients with cryopyrin-associated periodic syndromes","volume":"68","author":"Walker","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/rheumatology\/kex185","article-title":"Safety of vaccinations in patients with cryopyrinassociated periodic syndromes: a prospective registry based study","volume":"56","author":"Jaeger","year":"2017","journal-title":"Rheumatology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/rheumatology\/ken436","article-title":"Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept","volume":"48","author":"Borte","year":"2009","journal-title":"Rheumatology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1001\/jama.2013.6768","article-title":"Effects of the live attenuated measles-mumps-Rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis A randomized trial","volume":"309","author":"Heijstek","year":"2013","journal-title":"JAMA"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.vaccine.2020.01.037","article-title":"Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection","volume":"38","author":"Uziel","year":"2020","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/annrheumdis-2011-200637","article-title":"Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study","volume":"71","author":"Heijstek","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1177\/0961203310397409","article-title":"Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus","volume":"20","author":"Miyamoto","year":"2011","journal-title":"Lupus"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1016\/j.vaccine.2015.06.086","article-title":"Long-term safety and efficacy of varicella vaccination in children with juvenile idiopathic arthritis treated with biologic therapy","volume":"33","author":"Toplak","year":"2015","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1016\/j.vaccine.2017.04.015","article-title":"Varicella vaccination elicits a humoral and cellular response in children with rheumatic diseases using immune suppressive treatment","volume":"35","author":"Groot","year":"2017","journal-title":"Vaccine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12969-018-0231-3","article-title":"Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list","volume":"16","author":"Speth","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-018-0235-z","article-title":"The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey","volume":"16","author":"Jeyaratnam","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/acr.20183","article-title":"Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids","volume":"62","author":"Pileggi","year":"2010","journal-title":"Arthritis Care Res"},{"key":"B57","first-page":"791","article-title":"Paediatric rheumatology immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus","volume":"30","author":"Barbosa","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1590\/S1678-9946202163013","article-title":"Adverse events following yellow fever vaccination in immunocompromised persons","volume":"63","author":"Lara","year":"2021","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"B59","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/acr.20045","article-title":"Yellow fever revaccination during infliximab therapy","volume":"62","author":"Scheinberg","year":"2010","journal-title":"Arthritis Care Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0010002","DOI":"10.1371\/journal.pntd.0010002","article-title":"Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases","volume":"15","author":"Tonacio","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"B61","doi-asserted-by":"publisher","first-page":"100131","DOI":"10.1016\/j.jvacx.2021.100131","article-title":"Yellow fever vaccination in Brazil: short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases","volume":"10","author":"Emi Aikawa","year":"2021","journal-title":"Vaccine X"},{"key":"B62","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/annrheumdis-2022-222241","article-title":"Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases","volume":"81","author":"Kearsley-Fleet","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1093\/rheumatology\/keac103","article-title":"Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications","volume":"61","author":"Heshin-Bekenstein","year":"2022","journal-title":"Rheumatology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1093\/rheumatology\/keac105","article-title":"Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases","volume":"61","author":"Yeo","year":"2022","journal-title":"Rheumatology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1093\/rheumatology\/keac140","article-title":"Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases","volume":"61","author":"Akg\u00fcn","year":"2022","journal-title":"Rheumatology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/00325481.2022.2074700","article-title":"Safety of COVID-19 vaccines and disease flares after vaccines in children with rheumatic disease","volume":"134","author":"Arslanoglu Aydin","year":"2022","journal-title":"Postgrad Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac408","article-title":"Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases","author":"Ziv","year":"2022","journal-title":"Rheumatology"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1098332\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T21:40:12Z","timestamp":1673386812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1098332\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":67,"alternative-id":["10.3389\/fped.2022.1098332"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1098332","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"article-number":"1098332"}}